MUC16 and ovarian carcinoma: These findings emphasize the need for a variety of ovarian cancer biomarkers, to avoid solely focusing on biomarkers which rely on CA-125, while also supplementing the diagnostic value of CA-125 in related expressive ovarian cancers.